Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

PZ0192

Sigma-Aldrich

Bosutinib

≥98% (HPLC)

Sinônimo(s):

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile, SKI-606, WAY-173606

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C26H29Cl2N5O3
Número CAS:
Peso molecular:
530.45
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77

Ensaio

≥98% (HPLC)

forma

powder

cor

off-white to light brown

solubilidade

DMSO: ≥15 mg/mL

temperatura de armazenamento

room temp

cadeia de caracteres SMILES

COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl

InChI

1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)

chave InChI

UBPYILGKFZZVDX-UHFFFAOYSA-N

Informações sobre genes

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Bosutinib is a safe oral medicine with good bioavailability. It is effective for treating chronic myeloid leukemia (CML). It is also a potent ATP-competitive inhibitor for Src tyrosine kinase. Bosutinib inhibits epidermal growth factor receptor (EGFR). It suppresses solid tumors associated with breast, pancreas and prostate.

Ações bioquímicas/fisiológicas

Bosutinib (SKI-606) is an orally active; dual Src/Abl tyrosine kinase inhibitor with potent antiproliferative activity. It does not appear to inhibit c-Kit and PDGRF, which are thought to be the cause of numerous side effects in anticancer treatment with some other tyrosine kinase inhibitors.

Características e benefícios

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Abl page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Outras notas

Sigma-Aldrich is a licensed supplier of Bosutinib, providing the authentic Pfizer compound. The material is independently assayed and verified by both Pfizer and Sigma-Aldrich.

Informações legais

Sold for research purposes under agreement from Pfizer Inc.

Pictogramas

Exclamation mark

Palavra indicadora

Warning

Frases de perigo

Declarações de precaução

Classificações de perigo

Aquatic Chronic 4 - Eye Irrit. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Fluspirilene

Sigma-Aldrich

F100

Fluspirilene

Src Inhibitor-1 ≥98% (HPLC)

Sigma-Aldrich

S2075

Src Inhibitor-1

Lapatinib

Sigma-Aldrich

CDS022971

Lapatinib

Crizotinib ≥98% (HPLC)

Sigma-Aldrich

PZ0191

Crizotinib

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Daud AI, et al.
Clinical Cancer Research, 18(4), 1092-1100 (2012)
Sawsan M Amer et al.
Chemistry Central journal, 11(1), 136-136 (2017-12-24)
Masitinib (MST) is a selective tyrosine kinase inhibitor. Validated liquid chromatography tandem mass spectrometric method (LC-MS/MS) was developed for the quantification of MST in rat liver microsomes (RLMs) matrix. The developed method was applied to metabolic stability and excretion rate
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib.
Cortes JE, et al.
Blood, 118(17), 4567-4576 (2011)
Takeo Yasu et al.
Biological & pharmaceutical bulletin, 41(2), 254-258 (2017-12-08)
Ponatinib, a novel tyrosine kinase inhibitor marketed in 2016, is a key drug used for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. This study aimed to develop a simple method for determining plasma ponatinib concentration. The analysis
G Carmona et al.
Oncogene, 35(39), 5155-5169 (2016-03-22)
Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. How deregulation of actin regulators promotes cancer cell invasion is still enigmatic.

Artigos

Sigma-Aldrich offers many products related to Abl for your research needs.

Conteúdo relacionado

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica